2017 American Transplant Congress
CTLA4Ig Suppresses Memory Responses to HLA-A2+ Skin Grafts in a Mouse Model of Allosensitization by Reducing CD138+ Plasma Cells.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Purpose: In previous studies we demonstrated that CTLA4Ig suppresses de novo T-cell activation through blocking CD28 co-stimulation and attenuates recall alloantibody responses following re-exposure to…2017 American Transplant Congress
Desensitization Regimen for the Patients with High Isoagglutinin Titers to Undergo Adult ABO-Incompatible Living Donor Liver Transplantation.
Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Taoyuan, Taiwan
Background: Adult living donor liver transplantation can be performed across ABO blood type barrier successfully by depleting B cells using rituximab. However, the patients with…2017 American Transplant Congress
Persistence/Progression of Early Banff Borderline Changes (BBC) Is Associated with Chronic Renal Allograft Damage and Can Be Predicted by B Cell Cytokine Profile.
The clinical significance of early histological BBC in kidney transplant recipients (KTR) is unclear. It is also unknown if biomarkers predict progression to acute rejection…2017 American Transplant Congress
TACI Polymorphisms Associated with De Novo Alloantibodies in Humans and Allograft Rejection in Mice.
A. Trans-membrane Activator and CAML Interactor (TACI) controls B cell differentiation and memory and exists as numerous allelic variants among healthy individuals and individuals with…2017 American Transplant Congress
B Cells in Liver Transplant Tolerance.
In mice liver transplantation, the liver allografts can be accepted across fully mismatched MHC without immunosuppression. After transplantation, T cells infiltrate into the graft in…2017 American Transplant Congress
Effects of Tofacitinib (JAK-3 Inhibitor) on De Novo HLA-A2 Antibody Production in a Mouse Model of Allo-Sensitization.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Purpose: Tofacitinib is a Janus Kinase Inhibitor currently approved by FDA for treatment of rheumatoid arthritis. In considering its effect in reducing B cell proliferation…2017 American Transplant Congress
A Novel 3-Dimensional Culture System Enables In Vitro Study of Human Bone Marrow Plasma Cells.
Purpose: Historically, in vitro study of human plasma cells (PCs) has been greatly limited by their short survival (48-72 hrs). Therefore, systems that maintain viability…2017 American Transplant Congress
Importance of B Cell Antigen Specificity in Breg Dependent Tolerance.
Introduction: We have previously shown that anti-CD45RB induced islet and cardiac allograft tolerance is B cell dependent and can be adoptively transferred to naïve hosts…2017 American Transplant Congress
Prevention of Donor Specific Antibody Production After Skin Allografting by Mobilization of Endogenous Stem Cells Using a Combination of AMD3100 and Low-Dose FK506 in Rats.
Background: We have developed a stem cell mobilizing strategy that enables long-term liver and kidney allograft survival without sustained immunosuppression in small and large animals…2017 American Transplant Congress
A Prospective Iterative Trial of Carfizomib-Based Desensitization Trial: Initial Comparative Observations.
1U of Cincinnati, Cincinnati; 2Christ Hospital, Cincinnati
Carfilzomib (CFZ) is a 2nd generation proteasome inhibitor different form bortezomib in that it irreversibly disables 20s and 26s proteasomes.Results from the first 2 phases…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 35
- Next Page »